2011 IPO
Synergy Pharmaceuticals Stock
Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions.
Sign up today and learn more about Synergy Pharmaceuticals Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synergy Pharmaceuticals Stock
Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.
Funding History
| February 2009 | $15.9M |
|---|---|
| August 2010 | $400K |
| June 2011 | $1.2M |
| May 2016 | $89.8M |
| September 2017 | $300M |
Management
President & CEO
Gary S. Jacob
CMO
Patrick H. Griffin
CSO
Kunwar Shailubhai
Press
Wall Streets Journal - Dec, 14 2018
Synergy Pharmaceuticals Moves Forward on Path Toward SaleEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
